Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, аccording to long observations in real clinical practice.Material and methods. In study evaluated the data for 31 people (23 men and 8 women, the average age of those surveyed...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Столичная издательская компания
2023-03-01
|
| Col·lecció: | Рациональная фармакотерапия в кардиологии |
| Matèries: | |
| Accés en línia: | https://www.rpcardio.online/jour/article/view/2893 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|